MannKind Secures $50M Private Placement as FDA Clears Furoscix ReadyFlow
MNKD sits 84% above its 52-week low of $2.23.
Summary
MannKind raised $50 million in a private placement to cover a $45 million CVR payment triggered by FDA approval of Furoscix ReadyFlow, a new edema treatment. The deal includes pre-funded warrants and was priced at a 5% discount to market.
Key Events · Financing and Capital Events · MNKD
-
$50M Private Placement Priced at $3.89
MannKind sold 10.4 million shares at $3.89 each and pre-funded warrants for 2.4 million shares at $3.88 per warrant share, raising $50 million in gross proceeds. The price represents a 5% discount to the current $4.11 stock price.
-
Proceeds Earmarked for $45M CVR Payment
The net proceeds will fund a $45 million contingent value rights obligation triggered by the FDA approval of Furoscix ReadyFlow, with the remainder for general corporate purposes.
-
FDA Approves Furoscix ReadyFlow
The FDA approved Furoscix ReadyFlow (furosemide injection) for the treatment of edema in adults with heart failure or chronic kidney disease, expanding MannKind's cardiometabolic portfolio.
-
Pre-Funded Warrants Add Potential Dilution
Investors received pre-funded warrants to purchase 2.4 million shares at $0.01 per share, exercisable at any time with no expiration, adding potential dilution of approximately 0.7% of outstanding shares.
Analysis · MNKD · Life Sciences
A $50 million private placement priced at $3.89 per share—a 5% discount to the current $4.11 market price—will primarily fund a $45 million contingent value rights payment triggered by the FDA's approval of Furoscix ReadyFlow, which was also announced in this filing. The deal includes pre-funded warrants for 2.4 million shares, adding potential dilution, and was led by Frazier Life Sciences, a longstanding biotech investor whose participation signals institutional confidence despite the discount. While the concurrent FDA approval expands MannKind's cardiometabolic franchise, the immediate capital raise underscores cash constraints following a $16.6 million Q1 loss.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.6% of the 1569 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MNKD was trading at $4.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.23 to $6.51. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.